The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer (TRAIN-2): A randomized phase III trial.
 
Anna van der Voort
No Relationships to Disclose
 
Mette S. van Ramshorst
No Relationships to Disclose
 
Erik D. van Werkhoven
No Relationships to Disclose
 
Ingrid A. Mandjes
No Relationships to Disclose
 
Inge Kemper
No Relationships to Disclose
 
Annelie J. Vulink
No Relationships to Disclose
 
Irma M. Oving
No Relationships to Disclose
 
Aafke H. Honkoop
Consulting or Advisory Role - Lilly; Lilly
 
Lidwine W. Tick
No Relationships to Disclose
 
Agnes J. van de Wouw
No Relationships to Disclose
 
Caroline M. Mandigers
No Relationships to Disclose
 
Laurence J. C. van Warmerdam
No Relationships to Disclose
 
Jelle Wesseling
No Relationships to Disclose
 
Marie-Jeanne T.F.D Vrancken Peeters
No Relationships to Disclose
 
Sabine C. Linn
Consulting or Advisory Role - Daiichi Sankyo (Inst)
Research Funding - Agendia (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eurocept Pharmaceuticals (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Merck (Inst); Tesaro (Inst)
 
Gabe S. Sonke
Consulting or Advisory Role - Novartis (Inst)
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Roche (Inst)